Evogene Statistics
Total Valuation
Evogene has a market cap or net worth of $8.34 million. The enterprise value is $11.75 million.
Important Dates
The last earnings date was Thursday, March 6, 2025, before market open.
| Earnings Date | Mar 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evogene has 6.51 million shares outstanding. The number of shares has increased by 24.71% in one year.
| Current Share Class | 6.51M |
| Shares Outstanding | 6.51M |
| Shares Change (YoY) | +24.71% |
| Shares Change (QoQ) | +17.02% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 6.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.98 |
| Forward PS | 0.59 |
| PB Ratio | 0.56 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.38 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.17.
| Current Ratio | 1.15 |
| Quick Ratio | 0.90 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -352.54 |
Financial Efficiency
Return on equity (ROE) is -82.96% and return on invested capital (ROIC) is -58.86%.
| Return on Equity (ROE) | -82.96% |
| Return on Assets (ROA) | -30.52% |
| Return on Invested Capital (ROIC) | -58.86% |
| Return on Capital Employed (ROCE) | -104.92% |
| Revenue Per Employee | $59,937 |
| Profits Per Employee | -$116,092 |
| Employee Count | 142 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 2.83 |
Taxes
In the past 12 months, Evogene has paid $9,000 in taxes.
| Income Tax | 9,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.07% in the last 52 weeks. The beta is 1.11, so Evogene's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | -83.07% |
| 50-Day Moving Average | 1.46 |
| 200-Day Moving Average | 2.83 |
| Relative Strength Index (RSI) | 36.36 |
| Average Volume (20 Days) | 17,799 |
Short Selling Information
| Short Interest | 28,080 |
| Short Previous Month | 33,240 |
| Short % of Shares Out | 0.41% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.49 |
Income Statement
In the last 12 months, Evogene had revenue of $8.51 million and -$16.49 million in losses. Loss per share was -$2.89.
| Revenue | 8.51M |
| Gross Profit | 5.83M |
| Operating Income | -22.21M |
| Pretax Income | -21.46M |
| Net Income | -16.49M |
| EBITDA | -20.50M |
| EBIT | -22.21M |
| Loss Per Share | -$2.89 |
Full Income StatementBalance Sheet
The company has $15.31 million in cash and $2.50 million in debt, giving a net cash position of $12.81 million or $1.97 per share.
| Cash & Cash Equivalents | 15.31M |
| Total Debt | 2.50M |
| Net Cash | 12.81M |
| Net Cash Per Share | $1.97 |
| Equity (Book Value) | 14.84M |
| Book Value Per Share | -0.22 |
| Working Capital | 2.89M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$19.70 million and capital expenditures -$626,000, giving a free cash flow of -$20.33 million.
| Operating Cash Flow | -19.70M |
| Capital Expenditures | -626,000 |
| Free Cash Flow | -20.33M |
| FCF Per Share | -$3.12 |
Full Cash Flow StatementMargins
Gross margin is 68.48%, with operating and profit margins of -260.96% and -193.69%.
| Gross Margin | 68.48% |
| Operating Margin | -260.96% |
| Pretax Margin | -212.02% |
| Profit Margin | -193.69% |
| EBITDA Margin | -240.90% |
| EBIT Margin | -260.96% |
| FCF Margin | n/a |
Dividends & Yields
Evogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.71% |
| Shareholder Yield | -24.71% |
| Earnings Yield | -197.61% |
| FCF Yield | -243.66% |
Analyst Forecast
The average price target for Evogene is $12.00, which is 860.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.00 |
| Price Target Difference | 860.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on July 25, 2024. It was a reverse split with a ratio of 0.1:1.
| Last Split Date | Jul 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1:1 |
Scores
Evogene has an Altman Z-Score of -10.5 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.5 |
| Piotroski F-Score | 1 |